Pharma giant AstraZeneca plc (NASDAQ: AZN) pulled out of talks in Brussels in response to delays in the coronavirus vaccine delivery, a development that represents another escalation between the company and the European Union, as reported by Bloomberg.
European Union officials have been pressuring the company to rethink its decision to leave because they want to know about what has happened to vaccine deliveries, an official said. However, AstraZeneca has not confirmed its departure.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An online interview with AstraZeneca plc (AZN) CEO Pascal Soriot was published in the Italian La Repubblica in response to his company’s defense against the criticism leveled by the European Union on Tuesday. AstraZeneca CEO calls on the European Union to accept responsibility for the vaccine campaign’s delays, pointing out that the EU signed a deal with AstraZeneca three months later than the United Kingdom.
Since the EU insisted on receiving vaccine doses at precisely the same time as Britain, despite signing an agreement a three-months behind London, Astra has entered a “best-effort” agreement with the EU, which does not provide the exact amount of vaccine doses.
European Union claims to have advanced the company €336 million and is seeking explanations for the delay appearing to take place.
AstraZeneca plc (AZN) CEO, Soriot explained that the company plans to deliver the 3 million doses for the AstraZeneca and Oxford University vaccines within days of the EU’s regulatory approval, to reach 17 million doses in February.
